Poolbeg Pharma is a development-stage biopharmaceutical company with early-stage clinical assets and a growing R&D pipeline. It is well funded – in contrast to many companies at a similar stage of development – and has several catalysts over the next 12 months that could lead to the shares outperforming the peer group on a relative basis and creating value for shareholders on an absolute basis.
10 Jan 2023
Poolbeg Pharma: Catalyst-driven 2023 (10 for 23 extract)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Poolbeg Pharma: Catalyst-driven 2023 (10 for 23 extract)
Poolbeg Pharma PLC (POLB:LON) | 11.5 0.1 9.0% | Mkt Cap: 57.5m
- Published:
10 Jan 2023 -
Author:
Cavendish Research -
Pages:
6
Poolbeg Pharma is a development-stage biopharmaceutical company with early-stage clinical assets and a growing R&D pipeline. It is well funded – in contrast to many companies at a similar stage of development – and has several catalysts over the next 12 months that could lead to the shares outperforming the peer group on a relative basis and creating value for shareholders on an absolute basis.